Shares in Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) have rocketed more than 50% higher after the company announced positive clinical trial results for a treatment for Crohn’s Disease.

The biotechnology company, which focuses on finding treatments for immune-mediated inflammatory diseases, reported that three of four patients treated with its StemSmart treatment demonstrated a successful clinical response after receiving the mesenchymal stem cell (MSC) therapy.

And the fourth patient demonstrated a partial response, the company said.

It went on to say:

This is a remarkable result for patients who are living with debilitating complications of inflammatory bowel disease, which is often resistant to currently available approved therapies.

Few treatment options

The patients were approved for treatment under the special access scheme run by the Therapeutic Goods Administration, which allows for the use of new treatment options where no conventional therapies exist.

NSB Chief Executive Officer Nathan Smith said it was great news for the company.

He went on to say:

These treatment results provide critical validation of the StemSmart MSC platform in presenting a potential therapeutic solution to patients with debilitating fistulising Crohn’s disease that have limited effective treatment options. This data, along with our previous clinical trial results in refractory Crohn’s disease, provides a strong foundation for our commercialisation plans for StemSmart moving forward. Together, these early outcomes allow us to advance the development of a novel therapeutic in a responsible, informed, and patient-centred fashion as it supports and accelerates our progress toward clinical trial work later this year.

The company’s Chief Medical Officer, Dr Cathy Cole, said the response rate shown by the patients was “exceptional, given the serious, debilitating and long-standing adverse nature of their condition”.

She added:

If you consider that for these fistula patients treated with StemSmart, there were limited treatment options available, then the response to treatment is truly outstanding and offers hope for clinical recovery when there was previously little.

The StemSmart product is derived from adult human donor bone marrow-sourced MSC and is produced using a patented manufacturing process.

The company said in its ASX release that fistulising Crohn’s Disease was one of the most severe and debilitating complications of inflammatory bowel disease and was often resistant to the currently available therapies.  

NSB shares hit an early high of 17.5 cents, up 52.1% before settling back to be 34.8% higher at 15.5 cents.

The company was valued at $38.2 million at the close of trade on Monday.

The post Early success in battling Crohn’s Disease has sent this ASX biotech’s shares soaring appeared first on The Motley Fool Australia.

More reading

• As CBA shares struggle, is BHP set to retake the biggest ASX stock crown?
• Own VAS ETF? Here’s how your investment performed in 2025
• Why EOS, Elevra, Lynas, and New Murchison Gold shares are pushing higher today
• CBA vs. Westpac: Which is the better ASX bank stock for 2026?
• Which ASX defence ETF performed best in 2025?

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The S&P/ASX 200 Index (ASX: XJO) is having a strong session on Tuesday. In afternoon trade, the benchmark index is up 0.95% to 8,842.6 points.

Four ASX shares that are rising more than most today are listed below. Here’s why they are pushing higher:

Electro Optic Systems Holdings Ltd (ASX: EOS)

The EOS share price is up 11% to $11.12. On Monday, this defence and space company announced an agreement to acquire the MARSS counter-drone command and control business. It is a Europe-based provider of advanced software and AI systems used to detect, track, and respond to drone threats. EOS agreed an upfront cash amount of US$36 million (A$54 million) with a potential earn-out consideration of up to 100 million euros (A$174 million). This extra consideration is linked to how many new third-party contracts MARSS secures over the earn-out period.

Elevra Lithium Ltd (ASX: ELV)

The Elevra Lithium share price is up 9% to $9.98. This may have been driven by a broker note out of Macquarie Group Ltd (ASX: MQG). Its analysts have retained their outperform rating on the lithium miner’s shares with an improved price target. The broker lifted its valuation to reflect higher than expected lithium prices. Though, with its price target now at $8.50 (from $7.00), Elevra Lithium’s shares are trading comfortably ahead of this.

Lynas Rare Earths Ltd (ASX: LYC)

The Lynas share price is up 2.5% to $15.16. This is despite the rare earths producer revealing that its CEO, Amanda Lacaze, is retiring after 12 years in the role. Lynas’ chair, John Humphrey, remains positive on the company’s outlook despite the exit. He said: “It is thanks to Amanda’s hard work, drive and tenacity that Lynas is today a leading rare earths producer and critical supplier to global manufacturing supply chains. Under Amanda’s leadership, the company’s production and operating footprint has grown and our market value has increased from around $400 million in 2014 to close to $15 billion. This provides an excellent foundation for the company’s continued growth and development.”

New Murchison Gold Ltd (ASX: NMG)

The New Murchison Gold share price is up 10% to 5.6 cents. This morning, this gold miner announced high grade gold results from a reverse circulation drill program at the Lydia Gold Prospect. New Murchison Gold’s CEO, Alex Passmore, commented: “We are very pleased to provide this exploration update including high grade results for the Lydia gold prospect. Lydia sits on a granted mining lease very close to the Crown Prince Operation. We believe we can leverage off existing infrastructure (offices, maintenance facility, crusher, and sampling preparation facility) to bring Lydia online relatively quickly. NMG is working towards including Lydia into its resources and reserves inventory.”

The post Why EOS, Elevra, Lynas, and New Murchison Gold shares are pushing higher today appeared first on The Motley Fool Australia.

More reading

• Up 450% in a year, ASX All Ords gold stock leaping higher again today on exploration results
• Lynas shares slip on shock CEO exit
• Here are the top 10 ASX 200 shares today
• Why investors are watching this ASX defence stock today
• This lithium company has hit a new 12-month high on expansion news

Australia’s big banks remain a core part of many portfolios, particularly for investors seeking income, stability, and exposure to the domestic economy. But even within the same sector, there are meaningful differences in quality, execution, and long-term appeal.

As we move through 2026, a common question is whether Commonwealth Bank of Australia (ASX: CBA) or Westpac Banking Corp (ASX: WBC) is the better bank stock to own.

While both have their merits, I have a clear preference.

Why CBA stands out

CBA continues to set the standard among Australia’s major banks.

It has consistently delivered stronger returns on equity than its peers, reflecting superior cost control, pricing discipline, and balance sheet quality. Its technology investment over many years has also paid off, particularly in digital banking, where CBA remains well ahead of most competitors.

From an investor’s perspective, that operational strength translates into more reliable earnings. Even when conditions tighten, CBA has shown it can defend margins and maintain profitability better than most.

CBA’s premium valuation is often cited as a concern, and that is fair. The shares are not cheap on traditional metrics. But that premium exists for a reason. The market is effectively pricing in CBA’s track record of execution and its ability to compound earnings more consistently than other banks.

Westpac’s case for consideration

Westpac, on the other hand, offers a different proposition.

It typically trades at a lower valuation than CBA and often provides a slightly higher dividend yield. For income-focused investors, that can be appealing. Westpac has also made progress in simplifying its business and addressing legacy issues that weighed on performance in prior years.

However, Westpac’s earnings profile has been more uneven. It has faced greater challenges around cost growth, compliance, and execution, which have limited its ability to close the gap with CBA.

While Westpac is a solid bank, I don’t think it has demonstrated the same level of consistency over time.

Capital strength and dividends

Both banks are well capitalised and operate within a tightly regulated environment. Neither is taking excessive balance sheet risk, and both are expected to continue paying dividends in 2026.

That said, dividend sustainability matters just as much as headline yield. CBA’s stronger profitability provides me with greater confidence that dividends can be maintained through a range of conditions, even if growth is modest.

Westpac’s yield may look more attractive at times, but I think it comes with slightly higher uncertainty around earnings momentum.

The long-term view

For me, the choice comes down to quality.

If I am going to own a bank stock through different economic cycles, I want the one with the strongest franchise, the best execution, and the least need for constant monitoring. On that basis, CBA remains the standout.

Westpac can still play a role for investors seeking value or income, but as a long-term core holding, it does not quite match CBA’s consistency.

Foolish takeaway

Both CBA and Westpac are credible ASX bank stocks for 2026.

But if forced to choose just one, I would favour Commonwealth Bank. Its premium valuation reflects genuine strengths, not hype, and its track record suggests it is better positioned to deliver steady returns over time.

For investors who prioritise reliability over bargain hunting, CBA remains my preferred bank stock for the year ahead.

The post CBA vs. Westpac: Which is the better ASX bank stock for 2026? appeared first on The Motley Fool Australia.

More reading

• As CBA shares struggle, is BHP set to retake the biggest ASX stock crown?
• CBA shares could crash below $100 in 2026: Here’s why
• Building wealth: Here’s why I prefer ASX share buybacks to dividends
• How much passive income could I earn from Westpac shares
• Buy, hold, sell: CBA, CSL, and DroneShield shares

Motley Fool contributor Grace Alvino has positions in Commonwealth Bank Of Australia. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Global defence spending is soaring amid continuing geopolitical tensions around the world.

This led to many listed defence companies in aerospace, technology, and military equipment segments gaining major value in 2025.

Sara Pineros, a Quantitative Analyst at S&P Dow Jones Indices, said:

Aerospace & Defence ranked as the second-highest growth sector among the S&P Select Industries, posting a significant 46.8% increase, largely driven by rising geopolitical tensions worldwide.

Three ASX exchange-traded funds (ETFs) capturing this theme were launched in late 2024.

Here’s how they performed last year.

2025 performance: 3 ASX defence ETFs

Vaneck Global Defence ETF (ASX: DFND)

Over 2025, DFND ETF delivered a capital gain of 56% and closed the year at $36.74 apiece.

With dividends included, this ASX ETF gave a total return of 57%.

DFND ETF holds just 36 shares and tracks the MarketVector Global Defence Industry (AUD) Index before fees.

The top five holdings are Thales SA, RTX Corp, Leonardo SpA, Hanwha Aerospace Co Ltd, and Saab AB.

Thales is a French company that produces advanced defence electronics and cybersecurity systems.

RTX is a major US aerospace and missile systems manufacturer.

Leonardo is an Italian aerospace and defence company that makes helicopters.

Hanwha Aerospace is a South Korean company that makes military aircraft engines, artillery systems, and satellites.

Saab AB is a Swedish aerospace and defence company.

The DFND ETF is $44.30 per unit, up 1.8% on Tuesday.

It has a management fee of 0.65% per annum.

Global X Defence Tech ETF (ASX: DTEC)

Over 2025, DTEC ETF ripped 64% to $17.51 apiece and did not pay a dividend.

ASX DTEC invests in 37 shares and seeks to mirror the Global X Defense Tech Index before fees.

Global X explains DTEC’s differentiation from other ASX defence ETFs:

DTEC includes companies with a revenue filter ensuring exposure to AI, drones, and cybersecurity, capturing the future of innovation in defence.

The top five holdings are Lockheed Martin Corp, Rheinmetall AG, RTX Corp, Palantir Technologies Inc, and General Dynamics Corp.

Lockheed Martin builds air force fighter jets, missiles, and satellite systems.

Rheinmetall manufactures army tanks, weapons, and military vehicle systems.

Palantir is an AI and defence software company specialising in data analytics for government and defence industry clients.

General Dynamics builds submarines, combat vehicles, and provides defence IT services.

The DTEC ETF is $20.53 per unit, up 1.7% today.

The annual management fee is 0.5%.

Betashares Global Defence ETF (ASX: ARMR)

Over 2025, ARMR ETF soared 44% to $17.51 apiece and gave a total return of 48%.

ASX ARMR invests in up to 60 companies headquartered in NATO nations or allied countries, such as Australia, Japan, and South Korea.

It tracks the VettaFi Global Defence Leaders Index before fees.

The top five holdings are Lockheed Martin Corp, Rheinmetall AG, Raytheon Technologies Corp, Safran SA, and General Dynamics Corp.

Raytheon Technologies manufactures missiles, radar systems, and aerospace technology.

Safran builds aircraft engines and defence navigation systems.

Today, this ASX ETF is trading at $28.44 per unit, up 2.7%.

The yearly management fee is 0.55%.

The post Which ASX defence ETF performed best in 2025? appeared first on The Motley Fool Australia.

More reading

• Global X announces dividends for DTEC, WIRE and other ASX ETFs
• Forget AI – these ASX ETFs are riding a global megatrend with years of tailwinds ahead
• Why these ASX ETFs could be strong buys in 2026
• Own Betashares ASX ETFs? Here’s your next dividend

Motley Fool contributor Bronwyn Allen has positions in Betashares Global Defence ETF – Beta Global Defence ETF and Vaneck Global Defence Etf. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Palantir Technologies and RTX. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Lockheed Martin and Rheinmetall. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Kingsgate Consolidated Ltd (ASX: KCN) share price is heading lower on Tuesday after the gold producer released a fresh operational update.

At the time of writing, the Kingsgate share price is down 2.18% to $5.82. By comparison, the S&P/ASX All Ords Index (ASX: XAO) is currently up 0.9%.

Despite today’s move, it comes after a remarkable year for investors. The stock is now up over 340% over the past 12 months, making it one of the strongest performers in the ASX resources space.

So, what did the company announce?

Production remains strong

According to the release, Kingsgate reported that it produced 20,957 ounces of gold and 157,542 ounces of silver during the December 2025 quarter. That marked the fourth consecutive quarter in which gold production exceeded 20,000 ounces.

For the first half of FY26, total production reached 44,879 ounces of gold and 363,382 ounces of silver. Management noted that this result places the company at the midpoint of its FY26 production guidance, even though December was expected to be the weakest quarter of the year.

Cash position jumps sharply

Just as important for investors was the company’s update on its balance sheet.

Kingsgate finished the quarter with $179 million in cash, bullion, and dore, representing a 56% increase compared to the September quarter. That sharp rise was driven by higher gold prices, solid production, and improved operating performance.

This stronger cash position gives Kingsgate more flexibility. It can continue optimising its operations, strengthen its balance sheet, and position itself to benefit if gold prices remain elevated.

Gold price tailwinds remain supportive

Kingsgate’s strong year has also been helped by the broader rally in gold prices.

With gold trading at record levels after a strong run over the past year, producers have benefited from a more supportive pricing environment. That strength has fed into improved cash flow and helped underpin confidence in ASX gold stocks.

What investors should watch next

Looking ahead, the key focus will be whether Kingsgate can maintain production consistency and keep costs under control as it moves through the second half of FY26.

Further details are expected later this month when the company releases its full quarterly report for December 2025. That update should provide more insight into operating costs, margins, and how management plans to build on the strong start to the year.

For now, today’s update reinforces why Kingsgate has been back on investors’ radars and why the market continues to reward its progress.

The post Why this ASX gold stock is back in the spotlight today appeared first on The Motley Fool Australia.

More reading

• Investors tripled their returns with these ASX 300 shares this year

Shares in 4DMedical Ltd (ASX: 4DX) have been placed in a trading halt on Tuesday as the company seeks to raise fresh capital from investors.

According to the Australian Financial Review, term sheets are being circulated to investors offering $150 million worth of new shares at a price of $3.80 per share.

This would be a significant discount to the $4.29 the shares last changed hands for, with 4DMedical valued at $2.29 billion at that price.

Shares in the company have made significant gains over the past year, increasing from a low of 22.5 cents to a recent high of $4.84.

Key approval bolstering share price

Most of 4DMedical’s gains have come since August, when the company achieved US Food and Drug Administration approval for its CT:VQ technology, which is used in lung imaging.

Since winning approval, the company has been successful in signing contracts with four major health systems in the US, with one of those contracts, with UC San Diego Health (UCSD), secured just last week.

The company said in relation to that contract:

UCSD has commenced clinical use of CT:VQ under a structured launch framework whereby introductory pricing will apply through March 31, supporting early clinical adoption and workflow establishment, before transitioning to full commercial terms. UCSD joins Stanford University, University of Miami, and Cleveland Clinic as the fourth U.S. academic medical centre (AMC) to deploy CT:VQ for clinical use. This expanding network of leading AMCs powers 4DMedical’s strategic approach of establishing reference sites at the nation’s most prestigious institutions, creating a powerful foundation for broader market adoption. These deployments demonstrate the compelling clinical value proposition of CT:VQ: eliminating the need for radioisotope and contrast administration, providing superior image resolution compared to nuclear medicine, seamlessly integrating into existing CT imaging workflows, and enabling access to reimbursement pathways that support sustainable clinical adoption.

4D Medical founder and Managing Director Andreas Fouras said the new contract win was a “powerful validation” of the company’s technology.

He added:

In just over four months since FDA clearance, we’ve established CT:VQ at four of America’s leading academic medical centres: Stanford, University of Miami, Cleveland Clinic, and now UCSD. This rapid adoption by elite institutions demonstrates both the transformative potential of CT:VQ and the strength of our go-to-market execution. These prestigious AMCs serve as powerful anchors for our commercialisation strategy. Combined with our Philips partnership and growing commercial pipeline, we are building unstoppable momentum as we establish CT:VQ as the new standard of care in pulmonary imaging.

4DMedical shares are expected to return to trade by Thursday morning at the latest.

The post Why are 4DMedical shares in a trading halt today? appeared first on The Motley Fool Australia.

More reading

• Why 4DMedical, DroneShield, Super Retail, and Tamboran shares are falling today
• These three biotechs show how the sector can produce huge outsized gains, but are they still good value?
• Why 4DMedical, Regis Resources, Unico Silver, and WiseTech Global shares are pushing higher
• This biotech company’s shares are on a tear – again – after another contract win
• 3 of the fastest-growing stocks on the planet in 2025

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Income and growth are often treated as opposites in investing.

One is seen as defensive and steady, the other as aggressive and uncertain. But some of the most compelling long-term investments are ASX stocks that manage to deliver both.

They generate enough cash to reward shareholders today, while still reinvesting to grow earnings over time.

For investors looking to strike that balance at the start of 2026, here are two ASX stocks that offer a blend of income potential and long-term growth.

Flight Centre Travel Group Ltd (ASX: FLT)

Flight Centre has emerged from the post-pandemic period as a leaner and more focused business.

After navigating one of the most challenging periods in its history, the travel agent giant has rebuilt its earnings base around a streamlined cost structure and a stronger emphasis on its most profitable segments.

From an income perspective, the company is once again in a position to reward shareholders with a growing stream of dividends.

For example, Morgans believes the ASX stock will pay fully franked dividends of 52 cents per share in FY 2026 and then 61 cents per share in FY 2027. Based on its current share price of $15.17, this would mean dividend yields of 3.4% and 4%, respectively.

Morgans also sees plenty of upside for its share price. In response to the “strategically sound acquisition” of cruise agency Iglu, the broker said:

FLT’s strong balance sheet can comfortably fund this acquisition and its capital management strategy. We have upgraded our forecasts to reflect the acquisition of Iglu. Despite recent share price appreciation, FLT’s fundamentals remain attractive and we retain a Buy recommendation with a new A$18.38 price target.

Lovisa Holdings Ltd (ASX: LOV)

Lovisa is a very different kind of opportunity, but one that also manages to offer both income and growth.

The company operates a fast-fashion jewellery retail model that has proven highly scalable across international markets. Its ability to roll out stores quickly, maintain tight inventory control, and refresh product ranges frequently has underpinned strong returns on capital over time.

Looking ahead, the long-term growth story remains tied to store network expansion and execution in overseas markets. With relatively low penetration in many regions, Lovisa still has significant runway to grow its global footprint, while continuing to return capital to shareholders along the way.

Speaking of which, Morgans is expecting dividends of 92 cents per share in FY 2026 and then 114 cents per share in FY 2027. Based on its current share price of $29.57, this would mean dividend yields of 3.1% and 3.85%, respectively.

The broker believes recent share price weakness has created a buying opportunity for investors with this ASX stock. It said:

We see this as a great opportunity to buy this high quality retailer with a global store rollout opportunity trading back around its average 10-year 1-year forward PE multiple (~31x), offering ~20% EPS growth CAGR over the next 3 years. We have lowered our price target to $40 (from $44.50) driven by moving back to 50/50 weighting EV/EBIT and DCF valuation.

The post The best ASX stocks to buy in January 2026 if you want both income and growth appeared first on The Motley Fool Australia.

More reading

• 3 amazing ASX 200 growth shares to buy and hold for 20 years
• These are the 10 most shorted ASX shares
• Here are my top 10 ASX stocks for 2026
• 5 unbeatable ASX stocks I’m eager to buy in 2026
• These 2 ASX growth shares are ideal for Australians!

Motley Fool contributor James Mickleboro has positions in Lovisa. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Lovisa. The Motley Fool Australia has recommended Flight Centre Travel Group and Lovisa. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Thinking about where a business might be in 10 years’ time forces you to look beyond short-term earnings cycles and market sentiment.

The companies that are arguably best suited to a long holding period are those that can evolve as consumer behaviour changes, reinvest successfully, and expand their relevance over time. Size alone is not enough and adaptability matters just as much.

With that long-term lens, here are three ASX 200 shares that could still be building wealth for investors all the way through to 2036:

Breville Group Ltd (ASX: BRG)

Breville is often underestimated as a consumer appliances business. Its long term appeal lies in how it approaches product development and brand positioning.

Rather than competing purely on price, Breville focuses on premium, design-led appliances that sit at the higher end of the market. This gives it pricing power and allows it to build loyal customers who repeatedly upgrade within the ecosystem.

What makes Breville interesting over a decade-long timeframe is its global mindset. The company generates a large portion of its sales offshore and continues to invest heavily in innovation, particularly in coffee, food preparation, and connected appliances. As home cooking, coffee culture, and premiumisation trends persist globally, Breville has scope to deepen its presence in key international markets.

By 2036, Breville could potentially look less like a traditional appliance maker and more like a global consumer brand built around everyday rituals.

REA Group Ltd (ASX: REA)

Another ASX 200 share to buy and hold until 2036 is REA Group.

Its strength is not just its dominance in Australian property listings, but how embedded it has become in the real estate transaction process.

Realestate.com.au is often the first and last stop for buyers, sellers, and agents. That position gives the company powerful data advantages and the ability to layer new products and services on top of its core listings business.

Looking ahead to 2036, the opportunity is less about housing cycles and more about monetisation depth. REA Group continues to expand into analytics, finance-related tools, and agent services, increasing its relevance regardless of whether volumes are booming or subdued.

As long as property remains a core part of household wealth, platforms that control attention and data are likely to retain significant influence. REA’s challenge is execution, not relevance, which is a strong position to be in over the long term.

Temple & Webster Group Ltd (ASX: TPW)

Finally, Temple & Webster could be a top ASX 200 share to buy and hold.

It represents a different kind of long-term opportunity, one tied to how consumers shop rather than what they buy.

Furniture and homewares remain relatively underpenetrated online compared to other retail categories. Temple & Webster’s pure-play digital model allows it to avoid the fixed costs and inflexibility of physical store networks, while offering a far broader range than traditional retailers.

The long-term story is about leverage. As volumes grow, the company can spread marketing, technology, and logistics costs across a larger revenue base. Its growing private label offering also creates scope for margin expansion and differentiation.

If online adoption in bulky retail continues to rise over the next decade, Temple & Webster could still be in the early stages of its growth journey by 2036.

The post 3 of the best ASX 200 shares to buy and hold until 2036 appeared first on The Motley Fool Australia.

More reading

• Are these 2 ASX 200 media shares a bargain?
• 1 ASX dividend stock down 41% I’d buy right now
• How much passive income could I earn from Westpac shares
• Here are my top 10 ASX stocks for 2026
• This is a great place to invest $1,000 into ASX shares right now

Motley Fool contributor James Mickleboro has positions in REA Group and Temple & Webster Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Temple & Webster Group. The Motley Fool Australia has recommended Temple & Webster Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The All Ordinaries Index (ASX: XAO) is up 0.6% on Tuesday morning, with ASX All Ords lithium share Wildcat Resources Ltd (ASX: WC8) charging ahead of those gains.

Wildcat Resources shares closed yesterday trading for 41.5 cents. At time of writing, shares are changing hands for 42.5 cents each, up 2.4%.

Now, it was only back on 20 June that you could have picked up Wildcat shares for a mere 12.5 cents apiece. Brave investors who waded in and bought at the one-year lows on the day will now be sitting on gains of 240%.

That’s enough to turn an $8,000 investment into $27,200. In less than seven months.

Here’s what looks to be helping to boost the ASX All Ords lithium share again today.

ASX All Ords lithium share jumps on exploration results

Wildcat Resources shares are marching higher following an exploration update from the miner’s Bolt Cutter Central lithium discovery.

Bolt Cutter is located in Western Australia, some 10 kilometres from the company’s Tabba Tabba Project.

Today, the ASX All Ords lithium share announced the assay results from the remaining 14 drillholes of its 2025 drilling program at Bolt Cutter Central.

Top results from the full 2025 drill campaign included 20 metres at 1.70% lithium from 43 metres; and 12.8m at 2.02% Li2O from 45.3m.

Management said the latest results have significantly extended the interpreted strike extent of the mineralised pegmatite system.

According to Wildcat:

The scale of the discovery footprint highlights the potential for a large mineralised system with multiple stacked dykes of pegmatite which remain open in most directions. The final drilling completed during 2025 focused on completing a continuous drill section approximately 1.6 kilometres in length, aimed at defining the lateral extent of the mineralised pegmatite swarm.

The final batch of assay results confirmed mineralised pegmatite along the entire 1.6-kilometre section. Wildcat plans further exploration in what it labelled a highly prospective region.

What’s ahead for Wildcat Resources shares in 2026?

Looking to the year ahead, the ASX All Ords lithium share plans to kick off diamond drilling at Bolt Cutter Central later in January. Wildcat aims to expand the scale of the deposit and to collect samples to support Phase 1 metallurgical test work.

The lithium miner also plans to commence a reverse circulation (RC) drilling program towards the end of the first quarter of calendar year 2026.

The RC program will explore a range of potential targets to further extend mineralisation, as well as conducting infill drilling to advance towards a maiden Mineral Resource estimate for the project.

The post Up 240% since June, guess which ASX All Ords lithium share is jumping higher again on Tuesday appeared first on The Motley Fool Australia.

More reading

• 12 ASX lithium shares rip to 52-week highs
• Up 162% in 6 months! Expert tips this surging ASX lithium stock to double again

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares in Singular Health Group Ltd (ASX: SHG) were up more than 15% in early trade after the company said it had secured a key approval in the US.

The company said in a statement to the ASX that it had received 510(k) clearance from the US Food and Drug Administration for its product 3DICOM MD Cloud, as a Class II Software as a medical device.

This built on an earlier FDA clearance for the desktop 3DICOM MD software granted in October.

New technology more adaptable

The company said the cloud-based, browser-enabled version of the software removes the need for hardware and complex desktop installations, “lowering adoption barriers and improving usability for healthcare organisations”.

The 510(k) clearance allows the new version of the software to be marketed for use in the US.

The company went on to say:

The clearance represents a significant regulatory milestone and further strengthens Singular Health’s U.S. market strategy by expanding its regulated product portfolio. This clearance represents a significant step forward for Singular Health as it expands the company’s portfolio of regulated products and strengthens its U.S. commercial strategy.

Singular Health Managing Director Denning Chong said the FDA clearance was achieved well ahead of schedule.

He went on to say:

This clearance, achieved well ahead of time, represents a major milestone for Singular Health and our U.S. strategy. 3DICOM MD® Cloud removes many of the traditional barriers to adoption by eliminating the need for hardware and complex desktop installations, while expanding modality coverage to include X-ray and ultrasound. This positions the Company to scale faster and drive greater impact in reducing duplicate imaging.

Singular Health’s 3DICOM technology transforms medical scans into interactive 3D models.

The company said on Tuesday that the potential market for the technology was very large:

The company estimates a significant U.S. opportunity to address unnecessary duplicate imaging, with a total addressable market (TAM) of approximately US$16.5B. This estimate is based on direct imaging costs of US$236.5B and an estimated 7.7% duplicate occurrence across PET, CT, MRI, X-ray and ultrasound1. Importantly, X-ray and ultrasound were not supported in the previously cleared desktop version but are included in 3DICOM MD Cloud, materially expanding the range of clinical pathways and use cases the platform can support and broadening the Company’s addressable market.    

The company’s shares traded as high as 30 cents in early trade, up 15.4%, before settling back to be 9.6% higher at 28.5 cents.

The company was valued at $81.6 million at the close of trading on Monday.

The post This ASX biotech’s shares are up strongly on good news out of the US appeared first on The Motley Fool Australia.

More reading

• Why are 4DMedical shares in a trading halt today?
• The best ASX stocks to buy in January 2026 if you want both income and growth
• 3 of the best ASX 200 shares to buy and hold until 2036
• Up 240% since June, guess which ASX All Ords lithium share is jumping higher again on Tuesday
• Bell Potter says this ASX 300 stock is dirt cheap with 30%+ upside

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.